Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

BeiGene logo


Status and phase

Active, not recruiting
Phase 2


Nonsmall Cell Lung Cancer, Stage IV
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)


Drug: Tislelizumab
Drug: histology-based chemotherapy
Drug: Placebo
Drug: Ociperlimab

Study type


Funder types



CTR20212782 (Other Identifier)
2021-001075-17 (EudraCT Number)

Details and patient eligibility


This is a randomized investigator and participant blinded, sponsor unblinded, multicenter study that evaluates the safety and efficacy of ociperlimab with tislelizumab and histology-based chemotherapy compared with treatment with tislelizumab and histology-based chemotherapy in participants with previously untreated locally advanced, unresectable, or metastatic NSCLC


272 patients




18+ years old


No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  1. Histologically or cytologically documented locally advanced or recurrent NSCLC that is not eligible for curative surgery and/or definitive radiotherapy, with or without chemotherapy, or metastatic non-squamous or squamous NSCLC.

  2. No prior systemic therapy for locally advanced or metastatic squamous or non-squamous NSCLC, including but not limited to chemotherapy or targeted therapy. Participants who have received prior neoadjuvant, adjuvant chemotherapy, or chemoradiotherapy with curative intent for nonmetastatic disease must have experienced a disease-free interval of ≥ 6 months from the last dose of chemotherapy and/or concurrent radiotherapy prior to randomization.

  3. Archival tumor tissue or fresh biopsy (if archival tissue is not available) for the determination of PD-L1 levels and retrospective analyses of other biomarkers. Only participantswho have evaluable PD-L1 results are eligible.

  4. At least one measurable lesion by the investigator per RECIST v1.1.


  5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.

Key Exclusion Criteria:

  1. Known mutations in:

    • EGFR gene Note: For non-squamous NSCLC, articipants with unknown EGFR mutation status will be required to have a tissue-based EGFR test either locally or at the central laboratory before enrollment, or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-based EGFR test locally. Participants found to have EGFR-sensitizing mutations will be excluded.
    • ALK fusion oncogene.
    • BRAF V600E
    • ROS1
  2. Prior treatment with EGFR inhibitors, ALK inhibitors, or targeted therapy for other driver mutations.

  3. Any prior therapy targeting T-cell costimulation or checkpoint pathways in metastatic NSCLC.

  4. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before randomization.

  5. Infection (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before randomization.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Single Blind

272 participants in 2 patient groups, including a placebo group

Arm A: Ociperlimab + tislelizumab histology-based chemotherapy
Experimental group
Drug: Ociperlimab
Drug: histology-based chemotherapy
Drug: Tislelizumab
Arm B: Placebo + tislelizumab + histology-based chemotherapy
Placebo Comparator group
Drug: Placebo
Drug: histology-based chemotherapy
Drug: Tislelizumab

Trial contacts and locations



Central trial contact

BeiGene, USA, Inc

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems